In the Headlines
November 22, 2024
Dr. Oz’s Pharma, Medicare Views to Influence U.S. Drug Price Talks
Bloomberg Law
Healthcare attorney Melissa Wong spoke with Bloomberg Law about the uncertain future of the Medicare Drug Price Negotiation Program if Dr. Mehmet Oz is confirmed as head of the Centers for Medicare & Medicaid Services (CMS). The program, established by the Inflation Reduction Act, falls under CMS oversight. The article highlights that while Dr. Oz has previously criticized high drug prices, he has also shown support for pharmaceutical companies, raising questions about his approach to the program. Ms. Wong explained that the program also faces challenges from ongoing lawsuits and potential congressional action.
"Some of the guidance issued by CMS under this program was issued as recently as last month and full implementation as planned will take years," Ms. Wong noted. "That leaves Dr. Oz and the Trump Administration plenty of time to put their own stamp on the program, if it even survives all the lawsuits working their way through the courts and a possible repeal by Congress."
READ: Dr. Oz’s Pharma, Medicare Views to Influence U.S. Drug Price Talks (Subscription required)
"Some of the guidance issued by CMS under this program was issued as recently as last month and full implementation as planned will take years," Ms. Wong noted. "That leaves Dr. Oz and the Trump Administration plenty of time to put their own stamp on the program, if it even survives all the lawsuits working their way through the courts and a possible repeal by Congress."
READ: Dr. Oz’s Pharma, Medicare Views to Influence U.S. Drug Price Talks (Subscription required)